根据治疗持续时间,用于医疗治疗Graves甲状腺功能障碍的动态风险模型
Meihua Jin1, Chae A Kim2, Min Ji Jeon2
1Division of Endocrinology and Metabolism, Department of Internal Medicine, Dankook University College of Medicine, Cheonan, Korea.
Endocrinology and metabolism (Seoul, Korea)
|May 23, 2024
概括
甲状腺素受体抗体 (TRAb) 的变化预测了格雷夫斯病的复发. 使用TRAb模式的动态模型对于接受较长时间抗甲状腺药物 (ATD) 治疗的患者来说更准确,特别是那些持续时间较长的患者.
科学领域:
- 内分泌学 在内分泌学.
- 内部医学 内部医学
- 临床研究 临床研究
背景情况:
- 甲状腺素受体抗体 (TRAb) 水平与Graves的甲状腺功能障碍结果相关.
- 考虑到抗甲状腺药物 (ATD) 治疗持续时间,TRAb变化模式对预后的影响仍然不清楚.
研究的目的:
- 为了调查TRAb变化模式和Graves的甲状腺功能障碍预后之间的关联.
- 为了比较TRAb水平与TRAb变化模式的预测性能,与ATD治疗持续时间相关.
主要方法:
- 对1,235名格雷夫斯甲状腺功能障碍患者进行了回顾性队列研究,他们接受了超过12个月的ATD治疗.
- 患者根据ATD持续时间分为两组:12-24个月 (组1) 和>24个月 (组2).
- 风险预测模型的比较使用撤回时的TRAb水平 (模型A) 与TRAb变化模式 (模型B).
主要成果:
- 第二组 (>24个月ATD) 的复发率 (47.9%) 比第一组 (41.4%) 高得多.
- 第二组表现出更多的,甲状腺眼病和波动/燃烧的TRAb模式.
- 与单独的TRAb水平相比,TRAb变化模式独立预测了复发和预测准确度的提高,特别是在治疗持续时间较长的患者中.
结论:
- 结合TRAb变化模式的动态风险模型对于预测格雷夫斯甲状腺功能障碍的预后更为优越.
- 这种方法对于接受长期抗甲状腺药物治疗的患者尤其有价值.
相关概念视频
Synthesis and Regulation of Thyroid Hormones
4.5K
Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
4.5K
Chronopharmacokinetics: Circadian Rhythms and Influence on Drug Response
57
Circadian rhythms are cyclic changes that are crucial in plasma drug concentrations. Various standard circadian parameters, including core body temperature, heart rate, and other cardiovascular factors, directly impact disease states and the therapeutic response to drug therapy.
The time of drug administration is an important factor to consider, as it can influence the toxic dose of a drug. For example, a study conducted by Prins et al. in 1997 examined the effects of the timing of...
The time of drug administration is an important factor to consider, as it can influence the toxic dose of a drug. For example, a study conducted by Prins et al. in 1997 examined the effects of the timing of...
57
Renal Failure: Dose Adjustments
84
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
84
Rational Dosage Regimen: Maintenance Dose and Loading Dose
4.0K
A rational dosage regimen considers a drug's pharmacokinetics, including its absorption, distribution, metabolism, and elimination from the body. By understanding these factors, the appropriate dosage can be determined, and the dosing schedule can be designed to achieve and maintain the desired therapeutic effect while minimizing adverse effects.
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady...
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady...
4.0K
One-Compartment Open Model for IV Bolus Administration: General Considerations
194
The one-compartment model is a pharmacokinetic tool that models the body as a single, uniform compartment, facilitating the understanding of drug distribution and elimination. This model is particularly beneficial for intravenous (IV) bolus administration, where the drug rapidly circulates throughout the body.
The drug's presence in the body is defined by an equation representing the difference between the rates of drug entry and exit. Key parameters—elimination rate constant,...
The drug's presence in the body is defined by an equation representing the difference between the rates of drug entry and exit. Key parameters—elimination rate constant,...
194
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
972
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
972


